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The class IA phosphatidylinsositol 3-kinases (PI3Ks)
form a critical node in the insulin metabolic pathway;
however, the precise roles of the different isoforms
of this enzyme remain elusive. Using tissue-specific
gene inactivation, we demonstrate that p110a cata-
lytic subunit of PI3K is a key mediator of insulin
metabolic actions in the liver. Thus, deletion of
p110a in liver results in markedly blunted insulin
signaling with decreased generation of PIP3 and
loss of insulin activation of Akt, defects that could
not be rescued by overexpression of p110b. As a
result, mice with hepatic knockout of p110a display
reduced insulin sensitivity, impaired glucose toler-
ance, and increased gluconeogenesis, hypolipide-
mia, and hyperleptinemia. The diabetic syndrome
induced by loss of p110a in liver did not respond to
metformin treatment. Together, these data indicate
that the p110a isoform of PI3K plays a fundamental
role in insulin signaling and control of hepatic glu-
cose and lipid metabolism.
INTRODUCTION
The class I phosphatidylinsositol 3-kinases (PI3Ks) comprise
a family of phospholipid kinases activated by both receptor
tyrosine kinases (class IA PI3Ks) and G protein-coupled recep-
tors (class IB PI3Ks). Upon activation, these enzymes rapidly
catalyze the formation of phosphatidylinositol(3,4,5)-trisphos-
phate (PIP3 for short), which acts as an intracellular second
messenger by binding with high affinity to pleckstrin homology
(PH) domains in target molecules. Activation of class IA PI3K
by insulin and IGF receptors results in stimulation of downstream
pathways, leading to glucose uptake, glycogen synthesis,220 Cell Metabolism 11, 220–230, March 3, 2010 ª2010 Elsevier Inc.protein synthesis, proliferation, cell growth, and survival (Katso
et al., 2001; Cheatham et al., 1994; Taniguchi et al., 2006a,
2006b; Zhao et al., 2006). These metabolic growth effects
depend on activation of downstream kinases such as Akt/PKB
and the atypical isoforms of protein kinase C (PKC) (Taniguchi
et al., 2006a; Farese et al., 2005; Vanhaesebroeck et al., 1997;
Fruman et al., 1998; Geering et al., 2007; Engelman et al., 2006).
Class IA PI3Ks are heterodimers consisting of a regulatory
subunit, usually designated p85, and a catalytic subunit, desig-
nated p110. Both subunits of class IA PI3K, however, exist as
several isoforms. The catalytic subunit isoforms p110a, p110b,
and p110d are encoded by three genes, pik3ca, pik3cb, and
pik3cd, respectively. The p110a and p110b isoforms are ubiqui-
tously expressed, whereas p110d is predominantly expressed in
leukocytes (reviewed in Engelman et al., 2006). The precise
roles and relative contributions of individual catalytic subunits
of class IA PI3K in the multiple effects of PI3K in metabolism
and cell growth are still poorly understood. Mice with homozy-
gous germline deletion of p110a or p110b die early during
embryonic development (Bi et al., 1999, 2002), indicating
specific roles for each isoform during embryogenesis, but
limiting the information that can be gained about the roles of
these isoforms in adult tissues. Heterozygous deletion of either
p110a or p110b has no effect on insulin signaling, but mice
with heterozygous loss of both isoforms show an impaired insulin
response (Brachmann et al., 2005), suggesting that the two iso-
forms might play complementary roles in insulin action. We have
recently shown that liver-specific ablation of p110b had little
effect on insulin stimulation of Akt/PKB and showed only very
mildly impaired insulin sensitivity and glucose tolerance (Jia
et al., 2008). Similarly, Hirsch and colleagues showed that mice
with germline knockin of kinase-dead (KD) p110b (p110bK805R)
developed only mild insulin resistance even at 6 months of age
(Ciraolo et al., 2008).
The role p110a in insulin action is less clear.Micewith a hetero-
zygous germline knockin of a KD allele of p110a (p110aD933A)
develop insulin resistance and glucose intolerance as well as
hyperphagia and increased adiposity; however, this mutant
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Figure 1. Metabolic Phenotype of Mice with
Acute Hepatic Loss of p110a
(A) Fed and fasted blood glucose levels in mice of
the indicated genotypes were measured 12 days
after adenovirus injection (n = 8–10).
(B) Serum insulin levels in the fasted and random fed
states were measured 2 weeks after adenovirus
injection (n = 8–10).
(C) Glucose tolerance tests (GTT) on mice of indi-
cated genotypes 12 days after adenovirus injection
(n = 9).
(D) Insulin tolerance tests (ITT) on mice of indicated
genotypes 2 weeks after adenovirus injection.
Results represent blood glucose concentration as
a percentage of starting value at zero time (n = 7–9).
(E) Pyruvate challenge on mice of indicated geno-
types 16 days after adenovirus injection (n = 7–8).
(F) Quantitative RT-PCR analysis of mRNA levels of
phosphoenolpyruvate carboxykinase (pck1), glu-
cose 6-phosphatase (g6pc), fructose 1,6-bisphos-
phatase (fbp1), and hepatic nuclear factor-4a
(hnf4a) from the fasting mouse livers 3 weeks after
adenovirus injection.
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Role of Hepatic p110a in Metabolic Homeostasisp110a can compete with both wild-type p110a and p110b for
binding to regulatory subunits (Foukas et al., 2006). Chemical
inhibitors of p110a, but not inhibitors of p110b or p110d, have
also been shown to block insulin-stimulated phosphorylation of
Akt/PKB in 3T3-L1 adipocytes and L6myotubes and to decrease
glucose transport and insulin sensitivity in animals (Knight et al.,
2006), but their sites of tissue action are probably multiple and
remain unclear. To circumvent the limitations encountered in
these global inactivation and inhibition strategies in the present
study, we have addressed the role of the p110a isoform of
PI3K in hepatic insulin action by creating mice with acute or
long-term liver-specific deletion of p110a utilizing conditional
inactivation of the pik3ca gene (Zhao et al., 2006). Our data
demonstrate directly that liver p110a plays a critical role in the
metabolic actions of insulin and that disruption of this isoform
in liver results in impaired insulin action and glucose homeo-
stasis that cannot be rescued by p110b or ameliorated by met-
formin. In addition, deletion of p110a in liver creates a metabolic
crosstalk that affects other insulin-sensitive tissues, including
skeletal muscle and fat.
RESULTS
The liver plays a central role in mediating insulin’s metabolic
actions and glucose homeostasis. To investigate the impact of
p110a loss on hepatic insulin action, we created two mouse
models of deletion of p110a in liver (L-p110a): one acute, by
injection of adenoviruses expressing the Cre recombinaseCell Metabolism 11, 220–(Ade-Cre) into liver of 8- to 10-week-old
mice carrying homozygous floxed p110a
alleles (p110aloxp/loxp) (Zhao et al., 2006),
and one chronic, with early onset by
breeding the floxed mice with transgenic
mice carrying the Cre recombinase driven
by the albumin promoter (albumin-Cre)
(Taniguchi et al., 2006a). In both models,there was >90% reduction of p110a in the liver, while p110a
expression remained unchanged in livers of control mice, as
measured by western blot analysis (Figures S1A and S1B). In
both types of L-p110a knockout (KO) mice, we observed no
alterations of p110a levels in other tissues as compared to that
of controls (Figures S1A and S1B; data not shown). p110b
protein levels remained unaltered when p110a was ablated in
the liver (Figure S1B).
Effects of Acute Ablation of p110a in the Liver
Ade-Cre-mediated ablation of p110a in the liver of adult mice
resulted in a marked reduction of Akt/PKB phosphorylation in
response to insulin stimulation (Figure S1A). This acute liver-
specific loss of p110a resulted in 15%–20% increases in glucose
levels in both the fed and fasted state (Figure 1A) and a 4-fold
increase in fed and fasted serum insulin levels (Figure 1B).
Mice with acute L-p110a ablation also displayed impaired
glucose tolerance (Figure 1C) with no impairment in insulin
secretion (Figure S2A) and had reduced insulin sensitivity upon
challenge with an intraperitoneal (i.p.) insulin tolerance test
(ITT) (Figure 1D), all indicating insulin resistance secondary to
acute deletion of L-p110a.
Increased gluconeogenesis is one of the hallmarks of hepatic
insulin resistance in type 2 diabetes. To determine whether the
reduced insulin sensitivity and glucose tolerance in mice with
KO of p110a in liver were due to increased hepatic glucose
output, we subjected these animals to a challenge with pyruvate,
amajor gluconeogenic substrate. Administration of pyruvate had230, March 3, 2010 ª2010 Elsevier Inc. 221
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Role of Hepatic p110a in Metabolic Homeostasisno effect on blood glucose levels in control mice, but produced
an 25% increase in glucose in the L-p110a KO mice at 60 min
after administration (Figure 1E). This was associated with 1.5- to
2.5-fold increases in the expression of a number of enzymes and
transcription factors involved in gluconeogenesis, including
phosphoenolpyruvate carboxykinase (pck1), glucose 6-phos-
phatase (g6pc), hepatic nuclear factor-4a (hnf4a), and fructose
1,6-bisphosphatase (fbp1) in the L-p110a-deficient mice
(Figure 1F). Mice with acute ablation of p110a in liver also
showed a 34% reduction in serum free fatty acids, a 28%
reduction in total serum cholesterol, and a 44% reduction in
serum triglycerides compared with control animals, as well as
decreased lipogenic gene expression and hepatic triglyceride
content (Figures S3A–S3C), all of which were statistically signif-
icant. In addition, serum leptin levels and the expression of leptin
receptor in p110a-deficient livers increased approximately
8-fold relative to control (Figure S2B). This increase in circulating
leptin and hepatic leptin receptor expression is similar to our
previous finding in mice with severe hepatic insulin resistance
due to ablation of the insulin receptor gene in liver (Cohen
et al., 2007).
Effects of Chronic Loss of p110a in Liver
Insulin Signaling Is Impaired in p110a-Deficient
Hepatocytes
To determine effects of chronic deletion of p110a in liver, we
created a model of liver-specific inactivation by crossing mice
homozygous for the floxed allele of pik3ca with mice carrying
the albumin-Cre transgene (Taniguchi et al., 2006a). Chronic
loss of p110a in liver resulted in a dramatic reduction in the levels
of PIP3 in hepatocytes following insulin stimulation as assessed
by in situ immunofluorescence with anti-PIP3 antibody (Fig-
ure 2A). Thus, there was up to 10-fold elevation of PIP3 levels
in hepatocytes of control animals 5 min after insulin stimulation,
which declined over the next 10 min, whereas the induction of
PIP3 in response to insulin in L-p110a KO hepatocytes was
reduced by >60% (Figure 2A). This was associated with an
almost complete loss of IRS-1- and phosphotyrosine (PY)-asso-
ciated PI3K activity in livers of these mice in response to insulin
(Figure 2B) and a marked reduction in phosphorylation of Akt/
PKB, GSK3b, FoxO1, and p70S6K (Figure 2C). p110b-associ-
ated PI3K activity was almost undetectable in both the control
and L-p110a KO and was not changed at the basal or insulin-
stimulated state (Figure S1C), supporting recent reports that
p110b plays little role in insulin signaling (Jia et al., 2008; Ciraolo
et al., 2008; Knight et al., 2006). Taken together, these data indi-
cate that p110a is themajor PI3K catalytic subunit involved in the
hepatic insulin signaling.
Reconstitution of p110a Null Liver with p110a
versus p110b
To further investigate the importance of the PI3K p110a isoform
in insulin signaling in liver, we reconstituted the liver of L-p110a
KO mice with p110a, p110b, or a p110a KD mutant lacking its
kinase domain by tail vein injection of an adenoviral vector
directing expression of either of these genes. Expression of
wild-type p110a and p110bwere confirmed by immunoblot anal-
ysis using antibodies specific to the kinase domain (Figures 2E
and 2F). Expression of KD p110a was confirmed by quantitative
RT-PCR (Figure 2D). Reconstitution of L-p110a KO livers with222 Cell Metabolism 11, 220–230, March 3, 2010 ª2010 Elsevier Inc.wild-type p110a resulted in a restoration of insulin-stimulated
IRS-1- and PY-associated PI3K activity, as well as phosphoryla-
tion of Akt/PKB, GSK3b, p70S6 kinase, and FoxO1 to normal or
near-normal levels, whereas reconstitution with KD p110a had
no effect (Figures 2E and 2G). More importantly, when the
L-p110a KO mice were reconstituted by injection with adeno-
virus expressing p110b, insulin-stimulated phosphorylation of
Akt/PKB and other downstream components was not restored
(Figure 2F). In fact, increasing expression of p110b impaired
insulin signaling in control animals with reduced phosphorylation
of Akt/PKB, GSK3b, and p70S6 kinase. p85 protein levels were
not different between control and L-p110a KO mice and
were increased following p110a reconstitution (Figure 2E). This
was likely due to an overall increase in p110 concentration
(4-fold above normal by qRT-PCR), consistent with the known
ability of p110 to stabilize the regulatory subunit of PI3K (Yu et al.,
1998; Zhao et al., 2006). Thus, liver p110a is crucial for proper
insulin signaling in this tissue, and the effect of p110a loss on
liver insulin signaling cannot be compensated for by overexpres-
sion of p110b.
Physiological Characteristics of L-p110a KO Mice
L-p110a KOmice displayed mild adult-onset obesity. Starting at
10 weeks of age, male L-p110a KO mice showed more rapid
weight gain and by age 25 weeks weighed 9.4% more than
controls (46.5 ± 0.8 g versus 42.5 ± 1.5 g, p < 0.05) (Figure 3A).
Furthermore, male L-p110a KO mice had a 22.8% increase in
fat mass compared to controls, as measured by DEXA scanning
(p < 0.05) (Figure 3B). Female L-p110a KO mice exhibited
increased weight at 6 weeks of age and by 25 weeks weighed
6.3% more than controls (33.6 ± 2.3 g versus 31.6 ± 1.7 g, p <
0.05). DEXA scanning in females also indicated a trend toward
increased adiposemass (Figure 3B, p = 0.06). The samewas true
when the data were expressed as percent body fat: 31% ± 1.5%
in control males versus 35.7% ± 1.2% in L-p110a KOmales (p <
0.05); 31.9% ± 2.9% in control females versus 39.7% ± 1.9% in
L-p110a KO females (p = 0.06). Assessment of energy expendi-
ture, food intake, and activity in themale L-p110aKOand control
mice for 72 hr using CLAMS metabolic chambers revealed no
differences in O2 consumption, CO2 production, heat produc-
tion, respiratory exchange ratio, or food intake (data not shown).
However, male L-p110a KO mice did have a significantly lower
activity level than wild-type control mice (Figure 3C).
Despite the increase in body weight, both female and male
L-p110a KO mice had an 20% decrease in liver weight
compared to control animals (Figure 3B). In addition, male KO
mice had an 20% decrease in muscle weight (Figure 3B).
Neither male nor female KO mice differed in nose-tail length
compared to control animals (data not shown). Hepatic triglyc-
eride content in L-p110a KO mice was also similar to that in
the control animals (data not shown), and oil red O staining
revealed no alteration in accumulation of fat in the liver of
L-p110a mice (Figure S3D). Surprisingly, expression levels of
several lipogenic genes were decreased in the fed state in
L-p110a KO mice compared to control animals (Figure S3E).
While gluconeogenesis is mainly mediated via PIP3 activation
of Akt, hepatic lipid synthesis has been shown to be preferen-
tially mediated by atypical PKC (aPKC) downstream of PI3K
(Taniguchi et al., 2006a; Matsumoto et al., 2003; Standaert
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Figure 2. Hepatic Insulin Signaling in Mice
with Chronic Deletion of p110a
(A) Livers from control flox mice and mice with
chronic deletion of p110a were fixated, and liver
sections were stained with antibodies for PIP3
lipids at 00, 50, and 150 after vena cava insulin
or saline injection. Data represent mean ±SEM
(n = 4), *p < 0.05.
(B) PI3K activity from liver lysates immunoprecipi-
tated with phosphotyrosine (PY) or IRS-1 of fasted
mice of indicated genotypes (n = 4–5), *p < 0.05.
(C) Western blot of liver protein lysates from p110a
flox and L-p110a KO mice treated with saline or
insulin for 50 through inferior vena cava injection.
(D) Quantitative RT-PCR of p110a (pik3ca) gene
expression in liver from mice injected with adeno-
virus expressing GFP, a wild-type p110a, or
a kinase-dead (KD) mutant of p110a lacking the
kinase domain.
(E) Western blot of liver lysates prepared from
p110a flox and L-p110a KO mice injected with
control adenovirus (GFP) or adenovirus expressing
a wild-type or a KD version of p110a. Mice were
treated with either saline or insulin for 50 through
inferior vena cava injection. (*The p110a antibody
does not recognize the truncated KD p110a.)
(F) Western blot of liver protein lysates prepared
from control flox and L-p110a KO mice subjected
to tail vein injection with control adenovirus
expressing GFP or adenovirus expressing p110b
and treatedwith saline or insulin for 50 through infe-
rior vena cava injection. Data are representative of
three separate experiments.
(G) PI3K activity from liver lysates immunoprecipi-
tated with phosphotyrosine (PY) or IRS-1 of fasted
mice of indicated genotypes injected with adeno-
virus expressing GFP, a wild-type, or a KD version
of p110a (n = 2–6).
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Role of Hepatic p110a in Metabolic Homeostasiset al., 2004; Sajan et al., 2009). Interestingly, activation of aPKC
in response to insulin stimulation was almost completely ablated
in L-p110a KO animals (Figure S3F), indicating that p110a
is required for insulin activation of this downstream serineCell Metabolism 11, 220–2kinase. Taken together, L-p110a KO
mice have smaller livers but normal
hepatic morphology and lipid content
despite impaired lipogenesis.
L-p110a KO Mice Are Glucose
and Insulin Intolerant
As predicted, chronic inactivation of liver
p110a resulted in insulin resistance on
glucose metabolism. Male L-p110a KO
mice had only slightly elevated fed and
normal fasting glucose levels (Figure 3D),
and female L-p110a KO mice showed
no difference in glucose levels compared
to controls (Figure 3D). However, both
female and male L-p110a KO animals
had marked elevated circulating insulin
levels that were 5- and 10-fold higher
than normal at 10 weeks of age, respec-
tively, and this hyperinsulinemia becamemore pronounced in male L-p110a KO mice at 18 weeks of
age (Figure 3E). Male L-p110a KO mice also had markedly
increased insulin levels in the fasted state (Figure 3E). As seen
upon acute deletion of p110a, mice with developmental ablation30, March 3, 2010 ª2010 Elsevier Inc. 223
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Role of Hepatic p110a in Metabolic Homeostasisof p110a also showed dramatically increased serum leptin levels
and leptin receptor expression levels in the liver, both at 8 weeks
(data not shown) and at 18 weeks (Figure S2C). In contrast to the
mice with acute deletion of p110a, however, there were no
dramatic differences in serum lipid levels between KO animals
and controls (Figure 3F).
Both L-p110a KO males and females exhibited significantly
impaired glucose tolerance upon glucose tolerance testing
(GTT) by 8 weeks of age, and this became more severe by
24 weeks of age (Figure 4A). ITTs indicated that these L-p110a
mice were also resistant to the effects of i.p. administrated
insulin on reducing blood glucose levels (Figure 4B). In contrast
to the acute mouse model of p110a deletion, mice with chronic
deletion of p110a displayed no difference in gluconeogenic
gene expression compared to flox control mice in either the
fed or fasted state (data not shown).
To obtain a more accurate estimation of hepatic glucose
production (HGP) in vivo, we performed hyperinsulinemic-eugly-
cemic clamps with D-[3-3H]glucose and [14C]deoxyglucose
infusions. L-p110a KO animals had a significantly impaired
peripheral glucose uptake, with a glucose infusion rate (GIR)
thatwas approximately 20%of that of the flox control (Figure 4C).
More importantly, while basal HGP in the chronic L-p110a KO
mice was not different from the flox controls (data not shown),
KO mice showed a 4.4-fold increase in HGP during the insulin
clamp (p < 0.05) (Figure 4D). Thus, chronic L-p110a KO mice
are markedly insulin resistant and have impaired glucose
tolerance as well as impaired suppression of HGP in response
to insulin.
Loss of p110a in the Liver-Induced Hyperglycemia
Cannot Be Ameliorated by Metformin
Metformin is the most widely used drug for the treatment of type
2 diabetes and is known to exert its effects primarily by inhibiting
hepatic gluconeogenesis (Hundal et al., 2000; Mithieux et al.,
2002). To investigate if metformin could reverse the insulin resis-
tance and hyperglycemia seen in the L-p110a KO mice, animals
were treated with 300 mg/kg BW/day for 3 weeks. Ob/ob mice,
a genetic model of obesity and type 2 diabetes, were included
as a positive control and showed improved GTT in response to
the metformin treatment (Figure 4E). In contrast, metformin
treatment did not lower serum glucose levels upon GTT or ITT
in L-p110a KOmice (Figures 4E and 4F), nor did metformin treat-
ment lower random fed serum glucose levels (Figure 4G). While
the mechanism of metformin in suppressing gluconeogenesis is
not clear, part of its activity is believed to be achieved by acti-
vating AMP-activated protein kinase (AMPK) in liver (Zhou
et al., 2001; Shaw et al., 2005). Consistent with the lack of
glucose effect, we did not observe AMPK phosphorylation or
the phosphorylation of its downstream target, ACC, following
metformin treatment in hepatocytes of L-p110a KO mice (dataFigure 3. Physiological Characteristics of Mice with Chronic Hepatic D
(A) Whole-body weight. Open circles, p110a flox control mice; filled circles, L-p1
(B) Tissue weight. Data represent mean ±SEM (n = 8–10), *p < 0.05.
(C) Activity level of male flox controls and L-p110a KO mice during 72 hr in me
genotypes.
(D) Serum glucose levels of p110a flox and L-p110a KO mice at 10 and 18 week
(E) Serum insulin levels of p110a flox and L-p110a KO mice at 10 and 18 weeks
(F) Serum lipid levels of p110a flox and L-p110a KO mice at 8 and 18 weeks, ran
Cenot shown). Thus, p110a in the liver is required for the metfor-
min’s effect on insulin sensitivity.DISCUSSION
In the present study, we have defined the exact roles of p110a in
liver in insulin metabolic action and whole-body glucose homeo-
stasis using two mouse models of liver-specific p110a inactiva-
tion. We found that ablation of p110a in liver by either approach
markedly impaired insulin signaling, as evidenced by diminished
phosphorylation levels of Akt/PKB and other downstream
components in response to insulin stimulation. This defective
insulin responsiveness led to hyperinsulinemia and hypergly-
cemia and, in the chronic L-p110a KOmice, reduced liver weight
and mild obesity. While PI3K has been known to be central to
insulin’s metabolic action (Katso et al., 2001; Cheatham et al.,
1994; Taniguchi et al., 2006a, 2006b; Zhao et al., 2006), our
data demonstrate that it is the p110a catalytic subunit that is
the primary PI3K required for the metabolic actions following
insulin receptor activation in the liver. Consistent with this, germ-
line knockin of a KD allele of p110b or acute liver-specific abla-
tion of p110b has little effect on the ability of insulin to activate
Akt/PKB in hepatocytes and only mildly impaired their insulin
sensitivity and glucose homeostasis (Jia et al., 2008; Ciraolo
et al., 2008), consistent with a prior pharmacologic study
showing that p110b plays little role in insulin-stimulated Akt/
PKB activation (Knight et al., 2006).
Lack of liver p110a resulted in an impaired insulin signal with
markedly decreased activation of downstream molecules,
including Akt/PKB, GSK3b, and p70S6 kinase. While it was not
surprising that this defect in signaling was restored by reintro-
ducing p110a in the liver, it was somewhat surprising that
increasing expression of p110b had no effect to rescue the
p110a deletion. Indeed, overexpression of p110b seemed to
further impair insulin signaling at the level of Akt/PKB, GSK3b,
and p70S6, suggesting very distinct roles of the two p110 iso-
forms in liver insulin signaling. This is consistent with growing
evidence that the two isoforms have markedly different roles in
cellular signaling, metabolism, and oncogenic transformation
despite their similar structure and substrate specificity (Jia
et al., 2008; Ciraolo et al., 2008; Funaki et al., 2000; Wymann
andPirola, 1998). The lipid kinase activity of p110b is significantly
lower than that of p110a (Beeton et al., 2000). Thus, the paradox-
ical negative effect of p110b overexpression may result from
differences in catalytic activity, subcellular localization, or a
loss in signal strength as the less active p110b isoform replaces
p110a in p85 complexes responding to limiting numbers of
activated insulin receptor. While mice heterozygous for either
p110a or p110b have no defect in glucose metabolism, miceeletion of p110a
10a KO mice. Data represent mean ±SEM (n = 8–10), *p < 0.05.
tabolic chambers. The inset shows the area under the curve (AUC) for both
s, random fed and fasted state.
, random fed and fasted state.
dom fed state.
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Figure 4. Metabolic Phenotype of Mice with Chronic Deletion of p110a
(A) Mice were given an i.p. injection of 2 g dextrose/kg BW after an overnight fast.
(B)Miceweregivenan i.p. injectionof1.25U/kgBWinsulin.Results representbloodglucoseconcentrationasapercentageofstartingvalueatzero time.Areaunder the
curve (AUC) was calculated with baseline = 100% of basal. Open circles, p110a flox; filled circles, L-p110a KO. Data represent mean ±SEM (n = 8–10), *p < 0.05.
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Role of Hepatic p110a in Metabolic Homeostasisheterozygous for loss of both p110a and p110b exhibited hyper-
insulinemia and glucose intolerance, suggesting some comple-
mentary role of these two isoforms (Brachmann et al., 2005).
Interestingly, this occurs with no measurable reduction in
insulin-stimulated Akt/PKB phosphorylation.
We have previously reported that LIRKO mice with liver-
specific disruption of insulin receptor and absent insulin sig-
naling in hepatocytes show impaired insulin sensitivity and
glucose tolerance, as well as reduced liver and muscle weight
(Michael et al., 2000a). Our data presented here indicate that
p110a is the primary insulin-responsive PI3K isoform respon-
sible for this phenotype, and thus, not surprisingly, L-p110a
KOmice share many of the features with the LIRKOmice, further
supporting the importance of p110a in liver insulin action. The
cause of the reduced muscle weight in mice with liver-specific
alterations is not clear but may relate to the marked hyperinsuli-
nemia resulting in a secondary desensitization of insulin and/or
IGF-1 signaling in muscle. Indeed, in LIRKO mice, there is a
15%–20% decrease in expression of insulin receptor in muscle
(Michael et al., 2000b). Alternatively, the hepatic insulin resis-
tance in the L-p110a KO and LIRKO mice leads to alterations
in IGF-1 or IGF-1 binding proteins or changes in other signaling
pathways important for muscle growth.
Even though both liver and muscle weight are decreased in
L-p110a KO male mice, total body weight is increased due to
increased fat mass. L-p110a KO mice show no difference in
CO2 production, O2 consumption, RER, or food intake; however,
L-p110a KO mice do have a decreased activity level compared
to flox controls. Whether this leads to the increased body
weight or is a response to the increase in weight is unclear
(Tou and Wade, 2002). Interestingly, L-p110a KO mice have
significantly decreased peripheral (muscle) glucose uptake, as
indicated by the markedly decreased GIR during the hyperinsu-
linemic-euglycemic clamp, despite intact insulin signaling in
muscle (data not shown). Some of this decrease could be due
to the decrease in muscle mass. In any case, this marked
decreased response in muscle glucose uptake coupled with
the impaired insulin action of the liver could lead to a redistribu-
tion of substrates like glucose to white adipose tissue, where
they could be taken up and stored as fat, explaining the
increased fat mass observed in these mice despite no apparent
effect on food intake.
The increased fat mass observed in the L-p110a KO mice
was accompanied by increased circulating levels of leptin and
leptin receptor. Mice with liver-specific loss of the insulin
receptor also show increased leptin levels with increased
expression of both membrane-associated and -soluble forms
of the leptin receptor in liver and increased circulating leptin
receptor in serum (Cohen et al., 2007). Thus, alterations in insulin
signaling in liver can lead to increased circulating leptin for a
variety of reasons.(C and D) Insulin sensitivity quantified as glucose infusion rate (GIR) (C) and hepati
insulinemic-euglycemic clamp (n = 3–4), *p < 0.05.
(E) Mice were treated with metformin for 3 weeks, and GTT was performed by i.p.
as controls. The inset shows the AUC for untreated or metformin-treated ob/ob
(F) ITT was performed by i.p. injection of 1.25 U/kg BW insulin. Open circles, L-p1
ob/ob mice treated with 300 mg metformin/kg BW/day for 3 weeks. Data repres
(G) Serum glucose levels. Data represent mean ±SEM (n = 4).
CeBy employing both acute somatic and chronic developmental
ablation of p110a in the liver, we were able to identify any poten-
tial compensatory responses for p110a inactivation that might
occur in the development. Of note, we were also interested in
acute ablation, since it may mimic the clinical setting in cancer
patients treated with PI3K inhibitors, as in clinical trials currently
underway. In general, our findings in the acute and chronic
models of p110a deletion show many similarities, but also
a few interesting differences. Acute loss of p110a in liver resulted
in alterations in circulating lipids with decreased serum levels of
free fatty acids, cholesterol, and triglycerides, indicating a role of
the PI3K pathway in whole-body lipid homeostasis in the short
term. In the long-term KO mice, however, with the exception of
mild changes in triglycerides at young ages, the changes in these
lipids were not significant, suggesting that compensation by
other tissues, such as muscle and adipose tissue, might have
occurred. The decreased serum free fatty acid levels seen in
the older L-p110a KO mice may be due in part to a suppression
of lipolysis in the adipose tissue by the increased circulating
insulin levels. It is also possible that compensatory changes in
the liver itself have occurred, since the chronic KO mice show
normal levels of hepatic lipid content despite decreased aPKC
activity in response to insulin and decreased expression of
many of the genes involved in lipogenesis.
Metformin, a lipophilic biguanide, lowers blood glucose,
inhibits adipose tissue lipolysis, and improves whole-body
insulin sensitivity primarily by reducing hepatic glucose output
(Inzucchi et al., 1998; Stumvoll et al., 1998; Zhou et al., 2001).
Metformin is the most commonly used drug for type 2 diabetes
and would be a plausible drug to ameliorate the metabolic side
effects of chronic use of PI3K inhibitors in the treatment of
cancer patients. Unfortunately, metformin treatment neither
reduced the blood glucose levels in GTT nor improved the insulin
sensitivity in the L-p110a KO mice, suggesting that hepatic
p110a or one of its downstream targets is crucial for metformin
action. These data suggest that metformin is unlikely to amelio-
rate the metabolic side effects of PI3K inhibitors in cancer
patients and indicate that caution should be taken in treating
cancer patients who are diabetic or at high risk for developing
glucose intolerance.
In summary, our study demonstrates that p110a plays a critical
role in hepatic insulin/PI3K signaling and is required for normal
glucose and lipid homeostasis. Deletion of p110a in liver, either
developmentally or acutely, results in a marked reduction in
insulin-stimulated PI3K activity and altered whole-body glucose
homeostasis and insulin sensitivity. Since the PI3K pathway is
the major site of insulin resistance in type 2 diabetes (Cusi
et al., 2000 and others), it is possible that activators of this
pathway may be useful in treatment of type 2 diabetes. On the
other hand, our data raise concern that prolonged use of PI3K
inhibitors, especially those targeted against p110a, for thec glucose production (HGP) (D) in response to insulin were measured by hyper-
injection of 2 g dextrose/kg BW after an overnight fast. Ob/ob mice were used
mice.
10a KO or ob/ob mice treated without metformin; filled circles, L-p110a KO or
ent mean ±SEM (n = 3–4), *p < 0.05.
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may induce a variety of metabolic disorders, including overt
diabetes.
EXPERIMENTAL PROCEDURES
Animals
To create the chronic liver KO mice, p110a lox-lox mice were crossed with
mice hemizygous for the albumin-Cre recombinase transgene (Taniguchi
et al., 2006a). Mice were housed on a 12 hr light cycle and fed a standard
rodent chow (Lab Diet; Brentwood, MO) and water ad libitum. Metformin
(Sigma-Aldrich, St. Louis), wasmixedwith regular chow to deliver 300mgmet-
formin/kg BW/day for 3 weeks. Mice with an acute deletion of liver p110awere
created by tail vein injection of 2 3 109 pfu per mouse of adeno-Cre virus
(University of Iowa Gene Transfer Vector Core). All protocols for animal use
and euthanasia were approved by the Animal Care Use Committee of the
Joslin Diabetes Center, Dana-Farber Cancer Institute, and Harvard Medical
School in accordance with NIH guidelines.
Metabolic and Physiological Methods
Insulin was measured with ELISA (Crystal Chem Inc.; Downers Grove, IL).
Cholesterol, triglycerides (Stanbio Laboratory; Boerne, TX), and free fatty acids
(Wako USA; Richmond, VA) were measured with the colorimetric and enzy-
matic methods, respectively. GTTs were performed by i.p. injection of 2 g
dextrose/kg BW after an overnight fast. ITTs were performed by i.p. injection
of 1.25 U/kg BW insulin (NovoLog, Novo Nordisk Inc.; Copenhagen, Denmark).
The pyruvate challenge was performed by injecting 2 g/kg of pyruvate (Sigma-
Aldrich) i.p. after an 18 hr fast. Fat and lean mass were measured by dual-
energy X-ray absorptiometry (DEXA) scanning. CLAMS metabolic cage
studies were performed over a 3 day period following 1 day of acclimation.
Hyperinsulinemic-Euglycemic Clamp
The hyperinsulinemic-euglycemic clamp technique was performed as
described previously (Norris et al., 2003) with an insulin infusion of
3.5 mU/kg/min. Blood glucose was maintained at 130 mg/dl during the clamp.
HGP was assessed by subtraction of the GIR from whole-body glucose turn-
over as measured with D-[3-3H]glucose (Finegood et al., 1988).
In Vivo Insulin Signaling
Animals were fasted overnight and anesthetized with 2-2-2 Tribromoethanol
(Sigma; St. Louis), followed by injection of 5 U of insulin (NovoLog, Novo Nor-
disk Inc.) or saline via the inferior vena cava. Five minutes after the injection,
liver and muscle were excised, weighed, and snap-frozen in liquid nitrogen.
Adenoviral Injection
Adenoviruses for p110a and p110b were provided by T. Asano, Hiroshima
University, Hiroshima, Japan (Asano et al., 2000). The p110a KD mutant
adenovirus was created in the lab from a pcDNA3-p110a mutant vector (gift
of Lewis Cantley) that was derived from nucleotides 1–1731 of mouse pik3ca
cDNA (Klippel et al., 1994). The p110a KD adenovirus had an additional small
truncation of 31 bases at the 50 end of the pik3ca gene. Animals were injected
with 200 ml containing 10 3 1010 viral particles and sacrificed 4 days later
following vena cava injection with insulin or saline.
PIP3 Quantification and Liver Morphology Analysis
Following vena cava injection of insulin or saline, mice were perfused via the
heart with 10% neutral buffered formalin. PIP3 levels were measured by immu-
nofluorescence with a monoclonal antibody (IgM, Echelon Biosciences; Salt
Lake City, UT) as described (Kitamura et al., 2004). Sectioned liver samples
(10 mm) from four different mice were used for quantification. The fluorescence
intensity of 16 fields per slide was measured and analyzed with VH-H1A5
analyzer software (KEYENCE; Osaka, Japan). Liver morphology was analyzed
on livers from fixed mice by H&E staining.
In Vitro Kinase Assays
Livers were extracted into tissue homogenization buffer and subjected to
immunoprecipitationwith p110a, p110b, IRS-1, or PY for PI3K assays as previ-228 Cell Metabolism 11, 220–230, March 3, 2010 ª2010 Elsevier Inc.ously described (Ueki et al., 2000). Assays of aPKC activity were performed by
immunoprecipitation from liver lysates with a rabbit polyclonal antiserum
(Santa Cruz Biotechnology, Inc.; Santa Cruz, CA) that recognizes the C termini
of both PKC-l and PKC-z, collected on Sepharose-AG beads (Santa Cruz
Biotechnology) (Sajan et al., 2004).
Determination of Hepatic Triglyceride Content
Liver triglyceride content was measured as described previously (Wang et al.,
2009) using an enzymatic method (Serum Triglyceride Determination Kit,
TR0100; Sigma) and expressed relative to liver weight.
Antibodies
Actin antibody was from Santa Cruz Biotechnology; p85 antibody was from
Upstate-Millipore (Billerica, MA); and anti-vinculin antibody was from Sigma.
All other antibodies were from Cell Signaling Technology, Inc. (Danvers, MA).
RNA Extraction and Gene Expression Analysis
RNA was extracted by crushing frozen tissue in liquid nitrogen followed by
extraction using the RNeasy kit (QIAGEN; Valencia, CA). cDNA was prepared
using the High-Capacity cDNA Archive Kit (Applied Biosystems; Foster City,
CA) with random hexamer primers. Gene expression was analyzed by real-
time RT-PCR and ABI PRISM Sequence Detection System (Applied Biosys-
tems). Samples were normalized to 18S or GAPDH. Primer sequences are
available on request.
Statistics
All data are presented asmean ±SEM. The Student’s t test was used for statis-
tical analysis between two unpaired groups.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found with this
article online at doi:10.1016/j.cmet.2010.02.002.
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